Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of gene expression alteration in macrophage cells with oncolytic HSV

ABSTRACT: Identification of gene expression alteration in macrophage cells with oncolytic HSV

PROVIDER: PRJNA759634 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15691825_1.fastq.gz	Fastqsanger.gz
	SRR15691825_2.fastq.gz	Fastqsanger.gz
	SRR15691826_1.fastq.gz	Fastqsanger.gz
	SRR15691826_2.fastq.gz	Fastqsanger.gz
	SRR15691827_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 38

Similar Datasets

Transcription profiling of human MPNST cancer cells infected with G207 an oncolytic HSV

Project description:We used microarrays to identify genes regulated during oncolytic HSV infection. Oncolytic herpes simplex viruses (oHSV) are promising anticancer therapeutics. We sought to identify alterations in gene expression during oHSV infection of human cancer cells. Human malignant peripheral nerve sheath tumor (MPNST) cells were infected with G207, an ICP34.5-deleted oHSV previously evaluated in clinical trials. G207-infected cells demonstrated massive degradation of cellular mRNAs, while a subset were upregulated. A gene signature of 21 oHSV-induced genes contained 7 genes known to be HSV-induced. Go ontology classification revealed that a majority of upregulated genes are involved in Jak/STAT signaling, transcriptional regulation, nucleic acid metabolism, protein synthesis and apoptosis. Ingenuity-defined functional networks highlighted nodes for AP-1 subunits and interferon signaling via STAT1, SOCS1, SOCS3 and RANTES. Upregulation of SOCS1 correlated with sensitivity of MPNST lines to G207 and depletion of SOCS1 reduced virus replication >1-log. The transcriptome of oHSV-induced genes may predict oncolytic efficacy and provides rationale for next generation oncolytics. Experiment Overall Design: 5 human MPNST cancer cell lines were infected with G207 or mock infected for 6 hours followed by RNA extraction and hybridization on Affymetrix microarrays.

2008-06-16 | E-GEOD-8717 | biostudies-arrayexpress

Expression data from Human MPNST cancer cells infected with G207 and oncolytic HSV

2007-08-08 | GSE8717 | GEO

Engineering a novel HSV-1 strain for oncolytic therapy of solid tumors

Project description:Oncolytic HSV-1 derived viruses are being developed for cancer treatment. Here we describe the isolation of a novel strain of HSV-1, and its engineering to safely harness it as an oncolytic therapeutic. This strain (UT1a) was isolated from a de-identified consented patient biorepository. CRISPR-Cas9-based recombination was utilized to insert bacterial artificial chromosome (BAC) genes into the viral UL39 and UL40 locus resulting in the deletion of both large and small subunits of the viral ribonucleotide reductase (RR). Subsequent deletion of viral RL1 genes encoding the neurovirulence factor ɣ34.5, resulted in OncoDelta (OncoD), a virus deleted for UL39, UL40 and both copies of RL1. OncoD retained tumor cell specific cytotoxicity and replication, was safe and non-toxic in intracranial injections in naïve mice up to doses of (5 x 106), maximal injectable dose OncoD and showed significant anti-tumor immune activating potential in multiple tumor models. Transcriptome profiling of OncoD showed that it impaired DNA damage repair pathways and hence synergized with radiation to improve therapeutic response in vitro and in vivo.

2025-04-09 | GSE288846 | GEO

Identification of gene expression alteration in macrophage cells with oncolytic HSV

Project description:To evaluate signaling changes in macrophages upon oHSV treatment, we performed RNA-Seq from co-cultures of human GBM cells with murine macrophages

2022-03-31 | GSE183221 | GEO

Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing

Project description:single-cell RNA sequencing analysis on carcinomas treated with an HSV-2-based oncolytic virus to characterize the immunogenic changes in the TME

2021-11-01 | GSE186548 | GEO

Treatment of prostate cancer with oncolytic virus OH2 [bulkRNA-seq_tumors]

Project description:Prostate cancer is a major challenge due to limited treatment options in advanced stages. Immunotherapy has shown promising prospects in various cancers, but it faces obstacles in prostate cancer due to its immunosuppressive microenvironment and low response rate to current therapies. Oncolytic virus therapy provides a new immunotherapy approach by stimulating anti-tumor immune responses. This study investigated the histological changes of the novel herpes simplex virus type II (HSV-II) oncolytic virus OH2 in prostate cancer tumors.

2025-08-30 | GSE298912 | GEO

Engineering a novel HSV-1 strain for oncolytic therapy of solid tumors

Project description:Engineering a novel HSV-1 strain for oncolytic therapy of solid tumors

| PRJNA1219598 | ENA

A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner

Project description:Comparison of transcriptome data in tumors from mice treated with combinations of mitomycin C, oncolytic HSV-1, anti-PD-1 and anti-CTLA-4.

2022-03-01 | GSE195924 | GEO

Treatment of prostate cancer with oncolytic virus OH2 [bulkRNA-seq_C4-2]

2025-09-01 | GSE298913 | GEO

Treatment of prostate cancer with oncolytic virus OH2 [scRNA-seq_RM-1]

2025-09-01 | GSE298915 | GEO